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CC BY-NC-ND license (http://creativeAbstract Atrial fibrillation is the most common sustained arrhythmia and remains as one of
main challenges in current clinical practice. The disease may be induced secondary to other
diseases such as hypertension, valvular heart disease, and heart failure, conferring an
increased risk of stroke and sudden death. Epidemiological studies have provided evidence
that genetic factors play an important role and up to 30% of clinically diagnosed patients
may have a family history of atrial fibrillation. To date, several rare variants have been iden-
tified in a wide range of genes associated with ionic channels, calcium handling protein,
fibrosis, conduction and inflammation. Important advances in clinical, genetic and molecular
basis have been performed over the last decade, improving diagnosis and treatment. However,
the genetics of atrial fibrillation is complex and pathophysiological data remains still unravel-
ing. A better understanding of the genetic basis will induce accurate risk stratification and
personalized clinical treatment. In this review, we have focused on current genetics basis of
atrial fibrillation.
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Atrial fibrillation (AF) is the most common sustained
abnormal heart rhythm (arrhythmia) encountered in cur-
rent clinical practice. It is an erratic and unpredictable
activation of the atria, causing an irregular ventricular
response characterized by irregular waves in the electro-
cardiogram (ECG) which manifests clinically as fibrillation
pulse (Fig. 1).1 AF has a prevalence of 1% in the general
population, which increases with age to about 6% in peopleand hosting by Elsevier B.V. This is an open access article under the
4.0/).
Fig. 1 Diagram showing electrical activity of a normal heart (left) and a heart with atrial fibrillation (right). In a normal heart,
sino-atrial (SA) node starts electric signals whose induces contraction of auricles. Then, these electrical signals pass to ventricles
through atrio-ventricular (AV) node, inducing contraction of ventricles. In atrial fibrillation (AF) conditions, the normal beat in the
two auricles is irregular due to a chaotic electrical signal. It induces an irregular and fast heart beat which supposes that the blood
doesn’t flow correctly from the atria to ventricles.
258 O. Campuzano et al.over the age of 65 and approximately 10% of individuals by
80 years of age.2e4 Epidemiological studies suggest that AF
affects nearly 3 million people in the United States, 8.8
million Europeans, and 30 million individuals worldwide.5,6
With the accelerating aging population process and the
improved survival of patients with other cardiovascular
disorders, AF is estimated to increase 5-fold in prevalence
by 2050.7,8 Individuals with AF have nearly twice the risk of
death compared with the general population and it is
responsible for over 1/3 of all cardioembolic episodes.9
Recent guidelines suggested that AF be classified on the
basis of the temporal pattern of the arrhythmia.1,10
Therefore, AF may be paroxysmal (transient) or persis-
tent. Paroxysmal AF accounts for 35e40% of all cases seen
by physicians and is not a benign entity, especially in in-
dividuals with underlying cardiac pathology. The disease
carries a high mortality and despite being a self-terminating
arrhythmia, there is a 30e50% chance of converting to a
chronic state depending on the underlying pathology.11 AF
is generally known as a common complication in various
cardiac and systemic disorders including valvular heart
disease, hypertension, atherosclerotic disease and hyper-
thyroidism. In some cases, AF can also exist in the absence
of the previously mentioned predisposing factors, defined
as lone AF, and it accounts for 2e16% of all cases.12 Despite
the natural history of lone AF has not been well-studied,
current data suggest that it is associated with a low risk
of progression to permanent AF, mortality, congestive heart
failure, and stroke/transient ischemic attack.13,14
Taken all these data together, genetics play a key role
both as cause as well as modifier of the disease. According to
the patterns of heredity, AF could be familial following a
Mendelian hereditary pattern or non-familial AF, which
typically occurs in association with underlying cardiovascu-
lar disease. Therefore, genetic factors, interactingwith non-
genetic or environmental factors, contribute to the risk of
non-familial AF. Indeed, in 1936 the first report of familial AF
was published in three young brothers diagnosed with AF.15Seven years after, in 1943, Wolff et al published a family
with lone AF transmitted with an autosomal dominant
pattern of inheritance.16 Epidemiological studies have found
that individuals who have a first-degree relative with lone AF
carry up to 8-fold increased risk.17 Even more remarkable,
the presence of a clinically affected sibling is associatedwith
a 70-fold increased risk in males and 34 in females.18 The
Framingham Heart Study, which involved 2243 subjects,
identified that parental AF conferred a 1.85-fold increased
risk in offspring.19,20 A similar study from Iceland performed
in a cohort of 5269 patients corroborated the result, iden-
tifying a 1.77-fold increased risk of AF in first-degree rela-
tives.21 Finally, in a study of Danish twins, over 60% of the
variance of AF was estimated to be explained by genetics.22
Taking into account all these results, genetics play a critical
role in the development of lone AF. Finally, complications of
familial AF can occur at any age, although some people
suffering of AF never experience any health problems asso-
ciated with the arrhythmia.Genetics
Recent advances in genetics have given new insights into
the development of AF. Current efforts are focused on two
areas: genetic alterations and gene expression regulation in
ion channels. The gene expression studies are usually per-
formed in animal models. These experiments are princi-
pally providing information on the molecular changes
triggered by the disease and the mechanisms by which the
AF becomes chronic.23e25 Research in the identification of
genetic defects provides a direct link into the etiology for
AF. Genetic basis of AF can be currently studied from
different perspectives: 1) AF as a monogenic dis-
easeddifferent members of a family have the arrhythmia
as a primary electrical diseased, 2) arrhythmia presenting
in the setting of another familial disease, and 3) genetic
background that may predispose to the disease without
Table 1 Rare genetic variants associated with AF.
Gene Gene name
ABCC9 ATP-binding cassette, subfamily C, member 9
CACNB2 Calcium channel, voltage-dependent, beta 2
subunit
CACNA2D4 Calcium channel, voltage-dependent, alpha 2/
delta subunit 4
GATA4 Transcription factor GATA-4
GATA5 Transcription factor GATA-5
GATA6 Transcription factor GATA-6
GJA1 Connexin 43
GJA5 Connexin 40
GREM2 Gremlin-2
HCN4 Hyperpolarization activated cyclic nucleotide-
gated potassium channel 4
JPH2 Junctophilin-2
KCNA5 Potassium voltage-gated channel, shaker-
related subfamily, member 5
KCND3 Potassium voltage-gated channel, Shal related
subfamily, member 3
KCNE1 Potassium voltage-gated channel, Isk related
family, member 1
KCNE2 Potassium voltage-gated channel, Isk related
family, member 2
KCNE3 Potassium voltage-gated channel, Isk related
family, member 3
KCNE5 KCNE1-like
KCNH2 Potassium voltage-gated channel, subfamily H
(eag-related), member 2
KCNJ2 Potassium inwardly-rectifying channel,
subfamily J, member 2
KCNJ5 Potassium inwardly-rectifying channel,
subfamily J, member 5
KCNJ8 Potassium inwardly-rectifying channel,
subfamily J, member 8
KCNN3 Potassium channel, calcium activated
intermediate/small conductance subfamily N
alpha, member 3
KCNQ1 Potassium voltage-gated channel, KQT like
subfamily, member 1
LMNA Lamin A/B
NKX2.5 Homeobox protein Nkx2.5
NKX2.6 Homeobox protein Nkx2.6
NPPA Natriuretic peptide precursor A
NUP155 Nucleoporin 155
PITX2c Paired-like homeodomain 2c
RYR2 Ryanodine receptor 2
SCN1B Sodium channel, voltage-gated, type I, beta
subunit
SCN2B Sodium channel, voltage-gated, type II, beta
subunit
SCN3B Sodium channel, voltage-gated, type III, beta
subunit
SCN4B Sodium channel, voltage-gated, type IV, beta
subunit
SCN5A Sodium channel, voltage-gated, type V, alpha
subunit
SCN10A Sodium channel, voltage-gated, type X, alpha
subunit
SYNE2 Nesprin-2
ZFHX3 Zinc finger homeobox-3, transcription factor
Genes and atrial fibrillation 259family segregation The first two analyses are familial forms
of AF and require the segregation analysis of relatives, with
or without pathology. These familial forms are due to rare
variants in the population. The third case, research in non-
familial AF, is characterized by being multifactorial, the
result of the interaction of environment and genetic fac-
tors, which play a smaller role in the disease, albeit an
important one. It is due to common variants in the popu-
lation and the analysis is performed as an association study,
aimed at identifying differences in segregation of genetic
backgrounds which may explain the development of and
susceptibility to AF.26
Rare variants
In recent years, several rare genetic variants in genes
encoding ion channels or associated proteins have been
associated with AF.27 They could alter the depolarization/
repolarization of ion channels, leading to AF. To date, there
are published nearly 80 rare genetic variants in 39 genes
encoding different proteins like (Table 1): sodium ion
channels (SCN5A, SCN1B, SCN2B, SCN3B, SCN4B and
SCN10A), potassium (ABCC9, HCN4, KCNQ1, KCNA5, KCNJ2,
KCNJ5, KCNJ8, KCNE1, KCNE2, KCNE3, KCNE4, KCNE5,
KCNNE3, KCNH2 and KCND3) and calcium (RyR2, CACNB2
and CACNA2D4). In some of these cases carrying a patho-
genic variant in ion channels, AF has been described
concomitant with other monogenic diseases like Long QT
syndrome (LQTS)dEarly-onset AF (<50 years) is observed in
2% of LQTS patientsd,28e30 Brugada syndrome (BrS)dAF is
the most common atrial arrhythmia in Brugada syndrome
(BS), with an incidence reported between 6 and 53% by
different seriesd,31,32 Catecholaminergic Polymorphic
Ventricular Tachycardia (CPVT)dAtrial arrhythmias are
frequently observed in CPVT patients with an incidence of
10%d,33e35 and Short QT syndrome (SQTS).36 Concretely,
high incidence of atrial arrhythmias in patients with SQTS
has been reported with nearly 20%e25% of cases.37e41
In addition, rare variants in non-ion channels genes have
been also associated with AF such as in genes encoding gap
junctions (GJA1 and GJA5) as well as the NPPA gene,
encoding atrial natriuretic peptide (ANP),42 albeit with
precise molecular pathways yet to be established. More-
over, rare variants in LMNA, NUP155, JPH2, SYNE2 and
GREM2 (genes encoding structural proteins of nucleus and
involved in muscle function) have been identified in AF
cohorts, demonstrating abnormalities in cardiac excitation.
Finally, genes related to cardiac transcription factors have
also been identified as being associated with AF. Specif-
ically, genetic variation in ZFHX3, NKX2.5, NKX2.6, PITX2,
GATA4, GATA5, and GATA6 has been identified, although
the mechanisms whereby these lead to disease have
remained unclear.43e49
Common variants
In 2005, the genome-wide association study (GWAS) tech-
nique was utilized to identify genetic loci associated with
disease.50 Until this year, linkage and candidate gene
sequencing methods were the predominant approaches
used to identify AF genes. The first description of an
260 O. Campuzano et al.association between common single nucleotide poly-
morphisms (SNPs) and AF (chromosome 4q25, rs2200733),
using GWAS was performed in 2007.51 To date, several
common genetic polymorphisms have been associated with
the risk of AF development and risk of stroke, and predis-
pose to recurrences of AF on antiarrhythmic drugs or
ablation success.52 Hence, nearly 1/3 of all AF patients
carry common variants that predispose to AF.53,54 In gen-
eral, every single nucleotide polymorphism (SNP) only
carries a small relative risk, but they can be combined to
generate more precise information.55 A general contention
is that SNPs presumably act as promoters or enhancers of
proximate genes. Currently, it has been published 18 SNPs
being the 15 closest gene: PITX2, ZFHX3, KCNN3, CAV1,
PRRX1, C9ORF3, HCN4, SYNPO2L/MYOZ1, CAND2, GJA1,
NEURL, CUX2, TBX5, SYNE2, and WNT8A (Table 2).Future of genetics
Concerning rare variants already associated with AF, the
discovery of pathophysiology of ion channels may help un-
ravel the concise role played by the genetic variant in
arrhythmogenicity. However, most rare variants remain as
potentially pathogenic or of unknown significance and
translation into clinical practice should be done with
caution. It is necessary to clarify the role of interactions
between rare and common genetic variants in the predis-
position to AF.56 Thus, these variants, by mechanisms yet to
be understood, can interact to modify their respective
electrophysiological phenotypes.57 Some of the causative
variants in the identified AF loci remain unknown and some
of the discovered variants in these loci have yet to be
proven to be causative. This is a main challenge as several
SNP identified by GWAS are rarely the causative variants,
but a genetic marker in linkage disequilibrium with the
causative variation, which could remain still undetected
due to the fact that it is a non-coding insertion or deletion,Table 2 Common genetic variants associated with AF.
Locus SNP Nearest gene
4q25 rs6817105 PITX2
4q25 rs2200733 PITX2
16q22 rs2106261 ZFHX3
1q21 rs6666258 KCNN3
1q21 rs13376333 KCNN3
1q24 rs3903239 PRRX1
7q31 rs3807989 CAV1
14q23 rs1152591 SYNE2
9q22 rs10821415 C9ORF3
15q24 rs7164883 HCN4
10q22 rs10824026 SYNPO2L/MYOZ1
5q31 rs2040862 WNT8A
3q25 rs4642101 CAND2
6q22 rs13216675 GJA1
10q24 rs12415501 NEURL
10q24 rs6584555 NEURL
12q24 rs10507248 TBX5
12q24 rs6490029 CUX2a genetic rearrangement, a variation in copy number, or an
epigenetic modification,27 variants that still remain highly
unexplored.
The rare and common variants identified so far do not
seem to fully account for the considerable heritability of AF
observed in epidemiologic studies. There is a range of
possible explanations for this missing heritability, including
unidentified rare or common genetic variants, geneegene
interactions, geneeenvironment interactions or variations
in copy number (CNV). Current genetic technologies allow
performing a wide variety of analyses in families suffering
from AF in order to identify the single cause of AF or ge-
netic variants predisposing to the disease. Hence,
comprehensive large-scale exome and genome sequencing
for AF as well as GWAS studies will identify both rare and
common genetic variants associated with AF. In addition,
animal models and bioinformatic simulations may help to
clarify the cellular mechanism involved in pathophysiology
of AF.58
Conclusions
Currently, AF is the most common cardiac arrhythmia and is
associated with increased rates of heart failure, stroke, and
sudden death. Despite recent advances, current diagnosis,
treatment strategies and preventive measures have a
limited efficacy. It is mainly due to the complicated path-
ophysiology of the disease as well as to complicated in-
heritance mechanisms of the genes, which induce a
substantial interindividual variability leading to a varied AF
development. Furthermore, with regard to genetic variants
associated with AF, it is important to have a better un-
derstanding of molecular signaling events or mechanisms
that ultimately lead to the disruption of normal electrical
excitation. In the following years further genetic studies
will identify new genetic alterations associated with AF.
Molecular studies should definite corroborate theses geno-
typeephenotype associations in order to clarify the path-
ophysiological pathways leading to atrial arrhythmias.
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